Skip to content
2000
Volume 3, Issue 2
  • ISSN: 0250-6882
  • E-ISSN: 0250-6882

Abstract

Background

Based on the adverse event reporting system, the authors observed unique occupational and pharmacological trends in central serous chorioretinopathy (CSC); despite being a common condition in the region, there are no large epidemiological studies.

Objective

The study aims to describe the clinical profile, risk factors, and co-medications of CSC in a multispecialty hospital in the UAE.

Methods

Hospital based retrospective, observational study in which all the confirmed cases of CSC (272) seen between 2010 and 2019 were included. Supplementary data were collected on follow up visits or through telephonic calls.

Results

The male: female ratio was 17:1; low socio-economic status was (155; 73.45%), and occupations such as drivers (61; 28.9%) and outdoor laborers (59; 27.96%) were the most commonly affected. The majority (78.05%; 185) were single expatriates. Financial worries (105; 50.72%) constituted the leading cause of stress. The usage of corticosteroids (83; 30.51%), nasal decongestants (14.70%), or both (17; 6.25%) within one year was common; mostly (82; 30.14%) for rhinitis/respiratory states, though grossly under-recognized. Muscle relaxants and psychotropic medications were the other major medications used in 24 (8.82%) and 25 (9.19%) cases prior to CSC. Seven of 15 women had at least one condition that alters the endocrinal milieu: Pregnancy (3), recent child birth (1), erratic oral contraceptive intake (1), menopause with liver dysfunction (1), hormone replacement therapy for menopause and endometriosis (1), ovarian cyst and infertility (1) hypothyroidism (3), and cushing syndrome (1). Chronic/ recurrent forms were seen in 31.08%. There were too few glaucoma patients despite both CSC and glaucoma being common among our patients.

Conclusion

CSC in Al-Ain predominantly affected males with a specific occupational predisposition. Emotional distress, financial worries, allergic disorders, and endocrinal disorders (among females) were common. Adverse drug events were under-reported compared to the usage of steroid or decongestant users. Suspected pharmacological associations included drugs that modulated the vasomotor tone.

This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Loading

Article metrics loading...

/content/journals/nemj/10.2174/03666220428133215
2022-09-01
2025-01-19
Loading full text...

Full text loading...

/deliver/fulltext/nemj/3/2/NEMJ-3-2-04.html?itemId=/content/journals/nemj/10.2174/03666220428133215&mimeType=html&fmt=ahah

References

  1. von GraefeA. Über zentrale rezidivierende Retinitis.Graefes Arch. Clin. Exp. Ophthalmol.186612211215
    [Google Scholar]
  2. TittlM.K. SpaideR.F. WongD. PilottoE. YannuzziL.A. FisherY.L. FreundB. GuyerD.R. SlakterJ.S. SorensonJ.A. Systemic findings associated with central serous chorioretinopathy.Am. J. Ophthalmol.19991281636810.1016/S0002‑9394(99)00075‑610482095
    [Google Scholar]
  3. LiuB. DengT. ZhangJ. Risk factors for central serous chorioretinopathy: A systematic review and metaanalysis.Retina201636191910.1097/IAE.000000000000083726710181
    [Google Scholar]
  4. ErsozM.G. ArfS. HocaogluM. Sayman MuslubasI. KaracorluM. Patient characteristics and risk factors for central serous chorioretinopathy: An analysis of 811 patients.Br. J. Ophthalmol.2019103672572910.1136/bjophthalmol‑2018‑31243130002072
    [Google Scholar]
  5. MatetA. DaruichA. Behar-CohenF. Risk factors inCentral Serous Chorioretinopathy.Academic Press. ChhablaniJ. 20193547
    [Google Scholar]
  6. Carvalho-RecchiaC.A. YannuzziL.A. NegrãoS. SpaideR.F. FreundK.B. Rodriguez-ColemanH. LenharoM. IidaT. Corticosteroids and central serous chorioretinopathy.Ophthalmology2002109101834183710.1016/S0161‑6420(02)01117‑X12359603
    [Google Scholar]
  7. MichaelJ.C. PakJ. PulidoJ. de VeneciaG. Central serous chorioretinopathy associated with administration of sympathomimetic agents.Am. J. Ophthalmol.2003136118218510.1016/S0002‑9394(03)00076‑X12834690
    [Google Scholar]
  8. Said-AhmedK. MoustafaG. FawzyM. Incidence and natural course of symptomatic central serous chorioretinopathy in pregnant women in a maternity hospital in Kuwait.Middle East Afr. J. Ophthalmol.201219327327610.4103/0974‑9233.9792022837618
    [Google Scholar]
  9. ZhaoM. CélérierI. BousquetE. JeannyJ.C. JonetL. SavoldelliM. OffretO. CuranA. FarmanN. JaisserF. Behar-CohenF. Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy.J. Clin. Invest.201212272672267910.1172/JCI6142722684104
    [Google Scholar]
  10. JainM. Quetiapine associated Central Serous Chorioretinopathy: Implicit role of serotonin and dopamine pathways.Indian J. Ophthalmol.201967229229410.4103/ijo.IJO_929_1830672500
    [Google Scholar]
  11. Volpi-AbadieJ. KayeA.M. KayeA.D. Serotonin syndrome.Ochsner J.201313453354024358002
    [Google Scholar]
  12. Gungor KobatS. YusufogluE. GulF.C. KeserS. KalayciM. Plasma dopamine and catecholamine levels in patients with central serous chorioretinopathy.J. Fr. Ophtalmol.202144562162510.1016/j.jfo.2020.08.03233865632
    [Google Scholar]
  13. BujarboruaD. BorooahS. DhillonB. Getting serious with retinopathy: Approaching an integrated hypothesis for central serous chorioretinopathy.Med. Hypotheses201381226827310.1016/j.mehy.2013.04.03223669373
    [Google Scholar]
  14. KimuraT. ArakiT. KomukuY. IwamiH. GomiF. Central serous chorioretinopathy and blood serotonin concentrations.J. Clin. Med.202110455810.3390/jcm1004055833546112
    [Google Scholar]
  15. http://worldpopulationreview.com/countries/united-arab-emirates-population/
  16. WangM. MunchI.C. HaslerP.W. PrünteC. LarsenM. Central serous chorioretinopathy.Acta Ophthalmol.200886212614510.1111/j.1600‑0420.2007.00889.x17662099
    [Google Scholar]
  17. ScarinciF. MezzanaP. PasquiniP. CollettiM. CacciamaniA. Central chorioretinopathy associated with topical use of minoxidil 2% for treatment of baldness.Cutan. Ocul. Toxicol.201231215715910.3109/15569527.2011.61342721939432
    [Google Scholar]
  18. NuzziR. ScalabrinS. BeccoA. PanzicaG. Gonadal hormones and retinal disorders: A review.Front. Endocrinol. (Lausanne)201896610.3389/fendo.2018.0006629551993
    [Google Scholar]
  19. da CruzNFS PolizelliMU CezarLM CardosoEB PenhaF FarahME RodriguesEB NovaisEA Effects of phosphodiesterase type 5 inhibitors on choroid and ocular vasculature: A literature review.Int J Retina Vitreous2020638
    [Google Scholar]
  20. Gordon-BennettP. RimmerT. Central serous chorioretinopathy following oral tadalafil.Eye (Lond.)201226116816910.1038/eye.2011.25022056864
    [Google Scholar]
  21. TewariH.K. GadiaR. KumarD. VenkateshP. GargS.P. Sympathetic-parasympathetic activity and reactivity in central serous chorioretinopathy: A case-control study.Invest. Ophthalmol. Vis. Sci.20064783474347810.1167/iovs.05‑124616877418
    [Google Scholar]
  22. ArtunayO. SenelA. SengulA. RasierR. BahceciogluH. Central serous chorioretinopathy associated with topical latanoprost therapy.Ocul. Immunol. Inflamm.201119645345510.3109/09273948.2011.61968022106918
    [Google Scholar]
  23. Ayhan TuzcuE. KeskinU. CoskunM. IlhanO. DaglıogluM. OksuzH. Bilateral serous detachment associated with latanoprost/timolol fixed combination use: A report of one phakic case.Case Rep. Ophthalmol. Med.2012201230537910.1155/2012/30537923304588
    [Google Scholar]
  24. JainM. NevinR.L. AhmedI. Mefloquine-associated dizziness, diplopia, and central serous chorioretinopathy: A case report.J. Med. Case Reports201610130510.1186/s13256‑016‑1091‑427799060
    [Google Scholar]
  25. ImamuraY. FujiwaraT. SpaideR.F. Frequency of glaucoma in central serous chorioretinopathy: A case-control study.Retina201030226727010.1097/IAE.0b013e3181c2e0f419996820
    [Google Scholar]
  26. TsaiD.C. ChenS.J. HuangC.C. ChouP. ChungC.M. ChanW.L. HuangP.H. LinS.J. ChenJ.W. ChenT.J. LeuH.B. Risk of central serous chorioretinopathy in adults prescribed oral corticosteroids: A population-based study in Taiwan.Retina20143491867187410.1097/IAE.000000000000015924743638
    [Google Scholar]
  27. SahooN.K. SinghS.R. KammariP. JonnadulaG.B. DasA.V. ChhablaniJ. Prevalence and Profile of Central Serous Chorioretinopathy in an Indian Cohort.Nepal. J. Ophthalmol.2019112151010.3126/nepjoph.v11i1.2541031523060
    [Google Scholar]
  28. ReynoldsM.E. KareshJ.W. OhG.T. StahlmanS. Incident and recurrent cases of central serous chorioretinopathy, active component, U.S. Armed Forces, 2001-2018.MSMR2019269313431557049
    [Google Scholar]
  29. JamilA.Z. MirzaK.A. QaziZ.U. IqbalW. KhaliqJ. Fawad-ur-Rahman AhmedA. Features of central serous chorioretinopathy presenting at a tertiary care hospital in Lahore.J. Pak. Med. Assoc.201363447848223905445
    [Google Scholar]
  30. RouvasA.A. ChatziralliI.P. LadasI.D. XanthopoulouV. GiannakakiE. KaramboulaA. GalanisD. DatserisI. AlonistiotisD. DiamantiR. TsilimbarisM. ChalkiaA. TheodossiadisP. The impact of financial crisis on central serous chorioretinopathy in Greece: Is there any correlation?Eur. J. Ophthalmol.201424455956510.5301/ejo.500040324338576
    [Google Scholar]
  31. LajmiH. HmaiedW. Ben JalelW. AkremiA. El FekihL. Central serous chorioretinopathy: Professional repercussions among agents of the internal security forces.J. Fr. Ophtalmol.201841873974310.1016/j.jfo.2017.12.01230217609
    [Google Scholar]
  32. IslamQ.U. HanifM.K. TareenS. Frequency of systemic risk factors in Central Serous Chorioretinopathy.J. Coll. Physicians Surg. Pak.201626869269527539765
    [Google Scholar]
  33. BousquetE. DhundassM. LehmannM. RothschildP.R. BayonV. LegerD. BerginC. DiraniA. BeydounT. Behar-CohenF. Shift work: A risk factor for Central Serous Chorioretinopathy.Am. J. Ophthalmol.2016165232810.1016/j.ajo.2016.02.01226915576
    [Google Scholar]
  34. SetroukE. HubaultB. VankemmelF. ZambrowskiO. NazeyrollasP. DelemerB. DurlachV. DucasseA. ArndtC. Circadian disturbance and idiopathic central serous chorioretinopathy.Graefes Arch. Clin. Exp. Ophthalmol.2016254112175218110.1007/s00417‑016‑3378‑y27207466
    [Google Scholar]
  35. PenasS. CastroP. PereiraG. OliveiraA.M. CarneiroÂ.M. Rocha-SousaA. AzevedoE. Falcão-ReisF.M. Cerebral neurovascular coupling impairment in central serous chorioretinopathy.Ophthalmic Res.2020Epub ahead of print10.1159/00050955332564029
    [Google Scholar]
  36. MajumderP.D. MeniaN. SudharshanS. RaoC. GaneshS.K. BiswasJ. Clinical profile of uveitis patients developing central serous chorioretinopathy: An experience at a tertiary eye care center in India.Indian J. Ophthalmol.201967224725110.4103/ijo.IJO_831_1830672479
    [Google Scholar]
  37. KidoA MiyakeM TamuraH HiragiS KimuraT OhteraS TakahashiA OotoS KawakamiK KurodaT TsujikawaA Incidence of central serous chorioretinopathy (2011-2018): A nationwide population-based cohort study of Japan.Br J Ophthalmol2021Epub ahead of print10.1136/bjophthalmol‑2021‑319403
    [Google Scholar]
  38. BirchallW. CharlesS.J. BucklerH.M. Cyclical central serous chorloretinopathy associated with cystoid macular oedema.Br. J. Ophthalmol.200185675675810.1136/bjo.85.6.754‑d11426426
    [Google Scholar]
  39. ValenzuelaR.M. RaiR. KirkB.H. SandersJ.N. SundarS. HamannS. WarnerJ.E.A. DigreK.B. CrumA.V. JonesK.P. KatzB.J. An estimation of the risk of Pseudotumor Cerebri among users of the levonorgestrel intrauterine device.Neuroophthalmology201741419219710.1080/01658107.2017.130442529344058
    [Google Scholar]
  40. van DijkEHC de Roon HertogeKL BoonCJF Central serous chorioretinopathy. Central serous chorioretinopathy in a myopic patient with pachychoroid.Ophthalmology@point of care20171110.5301/oapoc.0000007
    [Google Scholar]
  41. MazumdarS. TripathyK. SarmaB. AgarwalN. Acquired myopia followed by acquired hyperopia due to serous neurosensory retinal detachment following topiramate intake.Eur. J. Ophthalmol.2019291NP21NP2410.1177/112067211879728630175623
    [Google Scholar]
  42. Muñoz MoralesA. Sánchez-VicenteJ.L. Franco RuedasC. de Las Morenas IglesiasJ. Espiñeira PeriñánM.Á. López-HerreroF. Macular neurosensory retinal detachment associated with topiramate use.Arch. Soc. Esp. Oftalmol.2019941261461810.1016/j.oftale.2019.07.01431610900
    [Google Scholar]
  43. YoshiokaH. KatsumeY. AkuneH. Experimental central serous chorioretinopathy in monkey eyes: Fluorescein angiographic findings.Ophthalmologica1982185316817810.1159/0003092397133631
    [Google Scholar]
/content/journals/nemj/10.2174/03666220428133215
Loading
/content/journals/nemj/10.2174/03666220428133215
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test